KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Return on Invested Capital (2023 - 2025)

Historic Return on Invested Capital for Recursion Pharmaceuticals (RXRX) over the last 3 years, with Q3 2025 value amounting to 0.73%.

  • Recursion Pharmaceuticals' Return on Invested Capital fell 400.0% to 0.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.73%, marking a year-over-year decrease of 400.0%. This contributed to the annual value of 0.63% for FY2024, which is 900.0% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Return on Invested Capital stood at 0.73% for Q3 2025, which was down 400.0% from 0.69% recorded in Q2 2025.
  • Recursion Pharmaceuticals' Return on Invested Capital's 5-year high stood at 0.58% during Q1 2025, with a 5-year trough of 0.86% in Q1 2024.
  • Its 3-year average for Return on Invested Capital is 0.71%, with a median of 0.71% in 2025.
  • Examining YoY changes over the last 5 years, Recursion Pharmaceuticals' Return on Invested Capital showed a top increase of 2800bps in 2025 and a maximum decrease of -400bps in 2025.
  • Recursion Pharmaceuticals' Return on Invested Capital (Quarter) stood at 0.77% in 2023, then increased by 21bps to 0.61% in 2024, then dropped by -20bps to 0.73% in 2025.
  • Its last three reported values are 0.73% in Q3 2025, 0.69% for Q2 2025, and 0.58% during Q1 2025.